RYR2 and non-small cell lung carcinoma: Figure 5 indicated that the TMB of patients with TP53, TTN, RYR2, LRP1B, FSIP2, and SPTA1 mutations was significantly higher than that of patients without these mutations for both NSCLC and SCLC.